Applied DNA Sciences (APDN) Misses Q4 EPS by 30c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Applied DNA Reports 2020 Year End and Fiscal Fourth Quarter Financial Results
December 17, 2020 4:05 PM EST- Receives Second Warrant Exercise Subsequent to Year-End for Net Proceeds of $1.05 Million
- Company to Hold Conference Call and Webcast Today, Thursday, December 17, 2020 at 4:30 PM ET -
STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2020.
Our activities in fiscal 2020 were principally devoted to the establishment of our diagnostic and surveillance testing... More
